<html><!-- #BeginTemplate "/Templates/0599Press Releases.dwt" -->

<head>
<meta name="" content="">
<meta name="" content="">
<!-- #BeginEditable "doctitle" --> 
<title>Public Citizen Health Research Group</title>
<!-- #EndEditable --> 
</head>

<body text="#000000" link="#0000FF" bgcolor="#CCCC99" vlink="#0000FF" alink="#0000FF">
<div align="center">
  <center>

<table width="600" bgcolor="#FFFFFF" cellpadding="0" cellspacing="0" align="center">
<tr align="center" valign="top">
<td>
<table border="0" width="600" cellspacing="0" cellpadding="0" align="center">
<tr valign="bottom">
<td align="center" width="15">&nbsp;</td>
<td align="center" width="360"> 
<p align="left"><font face="Arial, Helvetica, sans-serif" size="3" color="#666666"><img border="0" src="../../images/wirelogo.gif" width="350" height="55" alt="NewsWire" align="bottom"> 
</font>
</td>
<td align="center" width="225" valign="middle"> 
     
<p align="center"><font face="Arial, Helvetica, sans-serif" size="3" color="#666666">
<font color="#000066"><font size="1"><br>
</font></font></font><font face="Arial, Helvetica, sans-serif" size="3" color="#666666"><font color="#000066">
<script language="JavaScript">
var now=new Date();
var monthName=now.getMonth()+1;
var dayName=now.getDay()+1;
var dayNumber = now.getDate();
if(dayName==1)Day="Sunday";
if(dayName==2)Day="Monday";
if(dayName==3)Day="Tuesday";
if(dayName==4)Day="Wednesday";
if(dayName==5)Day="Thursday";
if(dayName==6)Day="Friday";
if(dayName==7)Day="Saturday";
if(monthName==1)Month="January";
if(monthName==2)Month="February";
if(monthName==3)Month="March";
if(monthName==4)Month="April";
if(monthName==5)Month="May";
if(monthName==6)Month="June";
if(monthName==7)Month="July";
if(monthName==8)Month="August";
if(monthName==9)Month="September";
if(monthName==10)Month="October";
if(monthName==11)Month="November";
if(monthName==12)Month="December";
document.open();
document.write( Day + "<br>"
 + Month + " " + dayNumber);
</script>
, 2000</font></font><font color="#006600" size="2" face="Arial, Helvetica, sans-serif"> 
</font>
</td>
</tr>
<tr valign="middle" align="left" bgcolor="#F4F4E1">
<td height="25"><font color="#000000"></font></td>
<td bgcolor="#F4F4E1" height="25"> 
<p align="left"><font color="#000000" size="1" face="Arial"> <font size="2" face="Arial, Helvetica, sans-serif" color="#006600"><b>Latest news from America's Progressive Community</b></font></font>
</td>
<td align="center" bgcolor="#F4F4E1" height="25"><font face="Arial, Helvetica, sans-serif" size="3" color="#000000"><font size="1"><a href="http://www.commondreams.org/search.html">Search</a> | <a href="http://www.commondreams.org/email.htm">Sign Up</a> | <a href="http://www.commondreams.org/privacy.htm">Privacy</a> </font></font></td>
</tr>
</table>
<table border="0" cellpadding="3" cellspacing="0" width="600">
<tr bgcolor="#E8E8E8" align="right" valign="middle"> 
<td width="600" colspan="5" height="25"> 
     
<div align="right"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>&nbsp;&nbsp;<a href="http://www.commondreams.org/">NewsCenter</a> 
&gt; <a href="http://www.commondreams.org/newswire.htm">NewsWire</a> </b></font><b><font face="Verdana, Arial, Helvetica, sans-serif" size="2">&gt; 
For Immediate Release&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></b></div>
</td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#E8E8E8" width="15" rowspan="7"> <font face="Arial, Helvetica, sans-serif" size="2"><a href="http://www.commondreams.org/wirearchive.htm">
</a></font> 
<p align="left"><font face="Arial, Helvetica, sans-serif" size="2"><small>
</small></font></p>
<p align="left">&nbsp;</p>
<p>
</td>
<td valign="top" align="left" bgcolor="#FFFFFF" width="20" rowspan="7">&nbsp;</td>
<td valign="top" align="left" bgcolor="#FFFFFF" width="530">
<div align="left"><font face="Arial, Helvetica, sans-serif" size="2"><a href="http://www.commondreams.org/share.htm"><br>
<img src="../../images/email.gif" width="25" height="14" alt="Email" border="0">&nbsp;Share This Article With A Friend</a></font></div>
</td>
<td valign="top" align="left" bgcolor="#FFFFFF" width="20" rowspan="7">&nbsp;</td>
<td valign="top" align="left" bgcolor="#E8E8E8" width="15" rowspan="7">&nbsp; </td>
</tr>
<tr> 
<td valign="top" align="left" width="530" bgcolor="#FFFFFF"><!-- #BeginEditable "Contact" --> 
<div align="left"><font size="2" face="Arial, Helvetica, sans-serif"><font color="#000000">MAY&nbsp; 
4, 1999&nbsp;&nbsp;10:24 AM<br>
<strong>FOR IMMEDIATE RELEASE<br>
</strong>CONTACT:<b> </b></font><b><a href="http://www.citizen.org/">Public Citizen</a><a href="http://www.citizen.org/hrg/"> 
Health Research Group</a></b></font></div>
<!-- #EndEditable --></td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#FFFFFF" width="530"></td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#FFFFFF" width="530"><font size="4" face="Arial, Helvetica, sans-serif"><b><!-- #BeginEditable "Header" --><font size="2" face="Arial, Helvetica, sans-serif"><b><font size="4">Public 
Citizen, National Women's Health Network Urge FDA to Require Warnings About Risks 
Associated with Tamoxifen Breast Cancer Drug Can Cause Endometrial Cancer, Other 
Serious Disease</font></b></font><!-- #EndEditable --></b></font></td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#FFFFFF" width="530">&nbsp; 
</td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#FFFFFF" width="530"><!-- #BeginEditable "Body" --><font size="2" face="Arial, Helvetica, sans-serif"><font color="#000000">WASHINGTON 
- May 4 - Public Citizen and the National Women's Health Network today <a href="http://www.citizen.org/hrg/WHAT'SNEW/1479.htm">petitioned</a> 
the U.S. Food and Drug Administration to require distribution of a patient Medication 
Guide outlining the risks to healthy women who are prescribed the breast cancer 
drug tamoxifen as a way to reduce the incidence of breast cancer. The petition 
also asks that the FDA revise the physician label for the drug.<br>
<br>
"Most women who are prescribed tamoxifen to reduce their risk of getting breast 
cancer are not fully apprised of the serious health consequences -- such as endometrial 
cancer or blood clots -- that may result," said Dr. Sidney Wolfe, director of 
Public Citizen's Health Research Group. "We believe the current FDA-approved label 
falls woefully short of providing the clear and accurate information women need 
to make this life-and-death decision."<br>
<br>
The petition urges the FDA to published two separate patient guides for tamoxifen 
(which is sold under the name Nolvadex) -- one for the treatment of breast cancer 
and one for the reduction in incidence of breast cancer. This would prevent patients' 
confusion over what information is relevant to them. These guides would include 
clinical studies, indications and usage, contraindications, precautions and adverse 
reactions. A revised physician label should separate the two main conditions for 
which the drug is used, better enabling physicians to interpret the risks and 
benefits.<br>
<br>
In the only completed clinical trial of tamoxifen's ability to reduce the incidence 
of breast cancer, 13,000 women at high risk of invasive breast cancer were followed 
for a median time of 4.2 years. Half of them took tamoxifen and half took a placebo. 
In the tamoxifen group, 2.2 percent developed breast cancer compared to 4.3 percent 
in the placebo group. However, the number of deaths from breast cancer, as well 
as deaths from all causes, were the same in the two groups.<br>
<br>
"Nothing less than the future health of many women is at stake," said Cindy Pearson, 
Director of the National Women's Health Network. "Women need to know that although 
they might have a slightly smaller chance of getting breast cancer by using tamoxifen, 
that benefit might be completely offset by the risk of contracting another deadly 
disease because of the drug. Unless these risks and benefits are clearly and fully 
stated, decisions become guesswork rather than rational choices."<br>
<br>
No one knows if the drug prevented breast cancer from occurring or if the cancers 
were delayed and appeared later. The study was too short to know if longer exposure 
to tamoxifen would cause other types of cancer to develop or whether the cancer 
rates might increase after women stopped taking the drug. Two European trials 
showed no difference in the number of breast cancer cases between women who took 
tamoxifen and those who got a placebo.<br>
<br>
Although tamoxifen produced a reduction of 2.9 cases of breast cancer per 1,000 
women per year in the U.S. study, it also increased by 2.8 cases per 1,000 women 
the number of life-threatening adverse events such as uterine cancer, blood clots 
and stroke. Tamoxifen is a known cancer-causing agent that increases a woman's 
chance of developing cancer of endometrium, or lining of the uterus.<br>
<br>
</font></font><FONT SIZE=2>
<P align="center"><font face="Arial, Helvetica, sans-serif" size="2">###</font></P>
<P align="center"><font face="Arial, Helvetica, sans-serif"><a href="http://www.citizen.org/hrg/WHAT'SNEW/1479.htm">Copy 
of petition available here.</a> </font></P>
</FONT><!-- #EndEditable --></td>
</tr>
<tr> 
<td valign="top" align="left" bgcolor="#FFFFFF" width="530"><font face="Arial" size="2" color="#000000">&nbsp; 
</font></td>
</tr>
<tr bgcolor="#E8E8E8"> 
<td valign="top" align="center" width="600" colspan="5" height="15">

<div align="center"><small><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Common Dreams <a href="http://www.commondreams.org/">NewsCenter</a></b>&nbsp;is a non-profit news service<br>
 providing breaking news and views for the Progressive Community.</font></small>
</div>
<p align="center"><font face="Verdana, Arial, Helvetica, sans-serif" size="1"><small>The 
press release posted here has been provided to Common Dreams NewsWire by  
one of the many progressive organizations who make up <a href="http://www.commondreams.org/community.htm">America's Progressive Community</a>. 
If 
you wish to comment on this press release or would like more information, 
please contact the organization  directly.<br>
 
</small></font><font size="1" face="Arial">*all times Eastern US (GMT-5:00)</font><font face="Arial, Helvetica, sans-serif" size="2"><small>
</small></font><font face="Arial, Helvetica, sans-serif" size="2"><small><br>
<br>
</small><b><font size="4">Making News?</font></b><br>
E-mail&nbsp;us your news release! <a href="mailto:news@newscenter.org">news@newscenter.org</a></font><font face="Arial, Helvetica, sans-serif" size="2"><small>
</small></font></p>
<div align="center">
<center>
</center>
</div>
<div align="center">
<center>
<font face="Arial, Helvetica, sans-serif" size="3"><b><a href="http://www.commondreams.org/">NewsCenter</a> 
| <a href="http://www.commondreams.org/newswire.htm">NewsWire</a><br>
 <font face="Arial, Helvetica, sans-serif" size="2"><a href="http://www.commondreams.org/search.html"><font size="1">Search</font></a><font size="1"> | <a href="http://www.commondreams.org/contactingus.htm">Contacting Us</a></font></font></b></font><font size="1"><b><font face="Arial, Helvetica, sans-serif"> | <a href="http://www.commondreams.org/email.htm">Sign-Up</a> | <a href="http://www.commondreams.org/privacy.htm">Privacy</a> </font></b></font><b><font face="Arial, Helvetica, sans-serif" size="2"><br>
</font></b>
</center>
</div>
<p align="left"><font face="Arial, Helvetica, sans-serif" size="2"><small>
</small></font>
<div align="center"><font face="Arial, Helvetica, sans-serif" size="2"><i>Tell Us What You Think:</i> 
 <a href="mailto:editor@newscenter.org">editor@newscenter.org 
</a><br>
 
</font><font face="Arial, Helvetica, sans-serif" size="1">
</font> 
 


</div>
<p align="center">
<font face="Arial, Helvetica, sans-serif" size="1">© Copyrighted 1997-2000
 
All Rights Reserved. Common Dreams. www.commondreams.org</font></p>
<p align="left"><font face="Arial, Helvetica, sans-serif" size="2"><small>
</small></font>
</td>
</tr>
</table>
<div align="center"></div>
</td>
</tr>
</table>

</center>
</div>
<p align="center">&nbsp;</p>
</body>

<!-- #EndTemplate --></html>
